Skip to main content
. 2020 Aug 26;131:104608. doi: 10.1016/j.jcv.2020.104608

Table 5.

. Characteristics and outcomes of ribarivin group in patients with pneumonitis and hepatic involvement.

Pneumonitis
Hepatic involvement
Variable Ribavirin (+) (n = 8) Ribavirin (-) (n = 35) p value Ribavirin (+) (n = 6) Ribavirin (-) (n = 69) p value
Lymphocyte count nadir (x106/L) [mean (SD)] 541 (186) 389 (221) 0.08 546 (197) 505 (327) 0.76
Lymphocyte count on admission (x106/L) [mean (SD)] 718 (389) 447 (241) 0.15 781 (429) 583 (381) 0.23
PaO2/FiO2 ratio* [mean (SD)] 254 (63) 297 (65) 0.17 262 (65) 379 (70) 0.001
Hospitalization duration in days [median (IQR)] 7.5 (6−9) 6 (4−7) 0.28 7.5 (5.75−9) 6 (5−7) 0.24
Age [mean (SD)] 38 (16.2) 35.9 (9.8) 0.65 36 (18.4) 32 (9.4) 0.48
Female, n (%) 4 (50) 15 (43) 0.71 3 (50) 39 (56.5) 0.76
ALT (U/L) [mean (SD)] 141 (188) 151 (138) 0.86 179 (206) 179 (126) 0.99

*Data from 21 patients (pneumonitis comparison) and 46 patients (hepatic involvement comparison).

ALT: alanine aminotransferase, FiO2: fraction of inspired oxygen, IQR: interquartile range, L: liter, n: number of patients, PaO2: arterial partial pressure of oxygen, SD: standard deviation, U: units.